At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2 enrolled
Drug / intervention
PEGPH20 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
In Brief
A clinical study evaluating PEGPH20, Cetuximab, and 2 other interventions for Pancreatic Cancer. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied. In Stage 2 of this study, the safety of cetuximab and PEGPH20 given before surgery will be studied. Also, the effects of PEGPH20 on tumors will be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsCold Spring Harbor Laboratory, Weizmann Institute of Science
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionSep 2016
TodayJul 2026
First PostedSep 16, 2014
Enrollment StartSep 12, 2014
Primary CompletionSep 13, 2016
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.8 years ago
Interventions
PEGPH20drug
Cetuximabdrug
DW & DCE-MRIdevice
blood drawsother
Blood samples will be drawn at various time points.